AMEX · VHAQ
Viveon Health Acquisition Corp.
$10.00$0.00 (0.0%)
Viveon Health Acquisition Corp.’s quoted price sits in the upper half of its reported 52-week range, 15.97% below the high.
Loading market information…
OTC · ANTH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Anthera Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Anthera Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:26 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2016 |
|---|
| Aug 9, 2016 |
| -$2.80-14.29% vs estimate |
| $0.00 |
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.00$0.00 (0.0%)
Viveon Health Acquisition Corp.’s quoted price sits in the upper half of its reported 52-week range, 15.97% below the high.
$0.00$0.00 (0.0%)
Sienna Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Comera Life Sciences Holdings, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Synovics Pharmaceuticals, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Neurobiological Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
SheerVision, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
OncoVista Innovative Therapies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$0.00$0.00 (0.0%)
Cotinga Pharmaceuticals Inc.: Healthcare · Biotechnology.
